ATNM Stock Forecast: Actinium Pharmaceuticals, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Actinium Pharmaceuticals, Inc. is $4. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 87 of 100 as at 21 Nov 2026 — inside the top quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Actinium Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (100): Sales and profits are climbing, and climbing faster than before.
Accruals (27): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ATNM stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ATNM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 Mar 2026 | Stephens & Co. | Reiterates | Overweight | — |
| 24 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Nov 2024 | Stephens & Co. | Reiterates | Overweight | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 Aug 2024 | Maxim Group | Maintains | Buy | — |
| 26 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2024 | Stephens & Co. | Initiates | Overweight | — |
| 2 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Apr 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ATNM.
This page is one stock. Monday covers all of them.
ATNM appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ATNM vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Actinium Pharmaceuticals, Inc. returned −18.6% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ATNM analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 4.0×
- Price / sales
- 1.2×
- Price / book
- 5.4×
- EV / EBITDA
- 1.6×
Cheaper than 88% of US stocks
Cheaper than 61% of US stocks
Cheaper than 17% of US stocks
Cheaper than 91% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 26.1%
- Net margin
- 30.3%
Higher than 85% of US stocks
Higher than 88% of US stocks
- Return on equity
- 55.2%
- Return on assets
- 12.9%
- Dividend yield
- —
Higher than 94% of US stocks
Higher than 95% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Actinium Pharmaceuticals, Inc. has a market value of $42.4M and an enterprise value of $14.9M.
Revenue in the twelve months to 30 June 2026: $35.1M.
Net income over the same four quarters: $11.3M, a 32.2% net margin.
Free cash flow in the twelve months to 30 June 2026: −$23.2M.
Trailing P/E: 4.0×.
Actinium Pharmaceuticals, Inc. employs 25 people — $1.4M of revenue per employee.
Data provided by Twelve Data
ATNM and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ATNM’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Actinium Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ATNM
What is the ATNM stock price forecast for 2026-2027?
The median 12-month analyst price target for Actinium Pharmaceuticals, Inc. is $4, with estimates ranging from $3 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ATNM stock a buy right now?
Of the 3 analysts covering Actinium Pharmaceuticals, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Actinium Pharmaceuticals, Inc. 87 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ATNM?
As at 21 Nov 2026, Actinium Pharmaceuticals, Inc. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (100 of 100).
Will ATNM stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts is $4, and Ticker Nerd's factor model ranks Actinium Pharmaceuticals, Inc. 87 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ATNM stock forecast for 2030?
No analyst covering Actinium Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ATNM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $7 over the next 12 months.
How has ATNM stock performed over the past year?
Actinium Pharmaceuticals, Inc. returned -18.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Actinium Pharmaceuticals, Inc. do?
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapies for cancer. Its current pipeline centers on antibody radiation conjugates and actinium-225-based programs designed to deliver radiation directly to tumor cells while limiting exposure to healthy tissue.
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapies for cancer. Its current pipeline centers on antibody radiation conjugates and actinium-225-based programs designed to deliver radiation directly to tumor cells while limiting exposure to healthy tissue. The company’s lead product candidate, ATNM-400, is being developed as a multi-indication therapy for solid tumors including prostate cancer, non-small cell lung cancer, and breast cancer. Actinium is also advancing Actimab-A for hematologic malignancies such as acute myeloid leukemia, along with Iomab-ACT for conditioning before gene and cell therapies. Through these programs, Actinium Pharmaceuticals, Inc. plays a specialized role in precision oncology, addressing both solid tumor and blood cancer settings with radiopharmaceutical approaches.
CEO Mr. Sandesh C. Seth M.B.A., M.S. · 25 employees · United States · https://www.actiniumpharma.com